Published: 20 November 2026 | 6.00 AM
Last Updated: 20 November 2026 | 6.00 AM
Integris Medtech IPO Snapshot
Integris Medtech IPO Snapshot
| Particulars | Details |
|---|---|
| Chanakya recommendation | Wait for pricing |
| Overall rating | 3/5, provisional |
| IPO opens on | 27 November 2026 |
| IPO closes on | 1 December 2026 |
| Allotment date | 2 December 2026 |
| Refund date | 3 December 2026 |
| Shares credited to demat accounts | 3 December 2026 |
| Listing date | 4 December 2026 |
| Price band | To be announced |
| Face value | Rs. 1 per share |
| Lot size | To be announced |
| Minimum retail application | Lots, shares and investment amount to be announced |
| Total IPO size | Pending pricing |
| Fresh issue size | Up to Rs. 600 crore |
| Fresh issue shares | Pending pricing |
| Offer for sale (OFS) | Up to 1,08,37,266 shares |
| OFS value | Pending pricing |
| Total shares offered | Pending pricing |
| Pre-IPO shares outstanding | 10,83,38,049 shares |
| Unofficial GMP | Unverified as of 20 November 2026 |
| Subscription status | Yet to open |
| Listing exchanges | BSE and NSE Mainboard |
| Lead managers | ICICI Securities, Axis Capital, Citigroup Global Markets India and IIFL Capital Services |
| Registrar | KFin Technologies |
The IPO timetable is tentative and subject to exchange confirmation.
The offer structure and intermediaries are disclosed in the draft prospectus and its addendum.
Investor Decision Box
| Investor consideration | Chanakya assessment |
|---|---|
| Listing gains | Wait for the price band and institutional subscription. |
| Long-term investment | Watchlist candidate, subject to valuation on recurring earnings. |
| Overall risk | Medium to high, given past losses, borrowing volatility and acquisition integration. |
👉 IPO GMP | IPO Reviews | IPO Subscription | IPO Allotment
Chanakya View
Wait for the price band. Integris Medtech’s FY25 operating revenue rose 22.5%, and the company returned to profit after two loss-making years. The June 2025 quarter’s Rs. 267.57 crore PAT included a Rs. 239.62 crore exceptional gain from the deemed disposal of investments. Post-issue P/E at the upper band is pending pricing and the final share count. Sahajanand Medical Technologies provides a cardiovascular reference and Molbio Diagnostics a diagnostics reference. The price relative to updated recurring earnings will determine the call.
About the Company
Integris Medtech develops, manufactures and sells cardiovascular devices, including drug-eluting stents and drug-coated balloons. Its laboratory business supplies instruments, reagents and consumables, alongside installation, maintenance and calibration services. It manufactures in India, Germany and the Netherlands and serves over 9,500 laboratories and 2,000 hospitals and catheterisation labs. Overseas markets contributed nearly 65% of FY25 operating revenue.
Why This IPO Stands Out
- Recurring demand potential. Laboratory consumables and servicing can generate repeat business after instrument placement.
- Improving operating profitability. FY25 EBITDA rose 62.5%, and EBITDA margin increased from 12.26% to 16.26%.
Key Risks
- Earnings volatility. Exceptional gains and charges have materially affected reported profit across periods.
- Borrowing swings. Debt more than doubled in FY25 before falling sharply by June 2025. Updated cash flows will help assess whether the reduction is durable.
- Acquisition integration. Combining overseas businesses adds operating complexity across markets.
Financial Snapshot (Rs. Crore)
| Restated consolidated | FY23 | FY24 | FY25 | Q1 FY26 |
|---|---|---|---|---|
| Operating revenue | 1,348.10 | 1,553.38 | 1,902.47 | 485.25 |
| EBITDA | 168.82 | 190.45 | 309.40 | 78.73 |
| PAT | −40.54 | −4.88 | 70.68 | 267.57 |
| Net worth | 2,629.52 | 2,681.02 | 2,752.52 | 3,889.99 |
| Borrowings | 556.54 | 813.10 | 1,729.46 | 793.42 |
FY25 EBITDA grew faster than operating revenue, while borrowings rose to 5.6 times EBITDA at year-end.
Business Quality Score
| Parameter | Chanakya score |
|---|---|
| Business model | 4/5 |
| Industry outlook | 4/5 |
| Financial performance | 3/5 |
| Management | 3/5 |
| Balance sheet | 2.5/5 |
| Growth potential | 4/5 |
IPO Proceeds and Why They Matter
| Proposed use | Amount |
|---|---|
| Repay or prepay borrowings of wholly owned subsidiaries | Rs. 93.87 crore |
| Repay or prepay borrowings of step-down subsidiaries | Rs. 415.98 crore |
| Total earmarked for debt repayment | Rs. 509.85 crore |
| General corporate purposes | Amount to be finalised |
The debt allocation represents about 85% of the proposed Rs. 600 crore fresh issue before expenses. The two repayment amounts are components of the total. Lower debt could ease interest costs. OFS proceeds go to the selling promoter.
Business Outlook
The clearest growth opportunity is selling more reagents, consumables and services to laboratories already using Integris equipment. Cardiovascular devices provide another avenue through its hospital network. Integrating acquired businesses across markets will test management’s ability to convert that scale into cash. After listing, track operating cash flow, interest costs and EBITDA margins to assess whether operating improvements and debt repayment translate into sustainable earnings.
Strengths vs Concerns
| Strengths | Concerns |
|---|---|
| Installed laboratory equipment supports repeat consumables and service sales. | Acquisition integration can complicate execution. |
| FY25 EBITDA grew faster than operating revenue. | Exceptional items have materially affected reported profit. |
Who Should Apply?
| Investor type | Chanakya assessment |
|---|---|
| Listing-gain investors | Wait for pricing and institutional subscription. |
| Long-term investors | Consider if recurring earnings support the offer valuation. |
| Conservative investors | Prefer evidence of sustained cash generation after listing. |
| Higher-risk investors | Reassess once pricing and updated financials are available. |
Chanakya Final Verdict
Wait for pricing. Provisional rating: 3/5. The proposed debt repayment could reduce financing costs, while the FY25 margin improvement supports the operating case. The June 2025 quarter’s profit included a substantial exceptional gain, making recurring earnings the more useful valuation benchmark. For listing gains, look for reasonable pricing and strong institutional demand. For long-term investment, assess the upper-band post-issue P/E using updated recurring earnings and check whether operating cash flow supports the improvement in margins.
Frequently Asked Questions
Should you apply for the Integris Medtech IPO?
Wait for the price band and assess valuation against recurring earnings.
When does the Integris Medtech IPO open and close?
The tentative subscription window is 27 November to 1 December 2026.
What is the minimum investment in the Integris Medtech IPO?
The amount depends on the price band and minimum bid lot, both awaited.
Short Summary
Integris Medtech combines cardiovascular devices with laboratory solutions. Debt repayment could strengthen its balance sheet. Chanakya’s call remains wait for pricing and assess valuation against recurring earnings.